These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26857693)

  • 21. A European perspective on orally inhaled products: in vitro requirements for a biowaiver.
    García-Arieta A
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):419-29. PubMed ID: 25238116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
    Usmani OS; Biddiscombe MF; Barnes PJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1497-504. PubMed ID: 16192448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimisation of DMPK by the inhaled route: challenges and approaches.
    Cooper AE; Ferguson D; Grime K
    Curr Drug Metab; 2012 May; 13(4):457-73. PubMed ID: 22299825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hood nebulization: effects of head direction and breathing mode on particle inhalability and deposition in a 7-month-old infant model.
    Kim J; Xi J; Si X; Berlinski A; Su WC
    J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):209-18. PubMed ID: 23808762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics.
    Guillon A; Sécher T; Dailey LA; Vecellio L; de Monte M; Si-Tahar M; Diot P; Page CP; Heuzé-Vourc'h N
    Int J Pharm; 2018 Jan; 536(1):116-126. PubMed ID: 29180257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using MRI to measure aerosol deposition.
    Thompson RB; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2012 Apr; 25(2):55-62. PubMed ID: 22463490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conference report: 1st Medicon Valley Inhalation Symposium.
    Lastow O
    Ther Deliv; 2013 Feb; 4(2):149-51. PubMed ID: 23343154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory toxicology considerations for the development of inhaled pharmaceuticals.
    Owen K
    Drug Chem Toxicol; 2013 Jan; 36(1):109-18. PubMed ID: 22273711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro/in vivo comparisons in pulmonary drug delivery.
    Newman SP; Chan HK
    J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):77-84. PubMed ID: 18518834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in predictive understanding of respiratory tract deposition.
    Finlay WH; Martin AR
    J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):189-206. PubMed ID: 18518795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical perspectives on pulmonary systemic and macromolecular delivery.
    Scheuch G; Kohlhaeufl MJ; Brand P; Siekmeier R
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):996-1008. PubMed ID: 16996638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Deposition of particles in the respiratory tract].
    Lieutier-Colas F
    Allerg Immunol (Paris); 2001 Feb; 33(2):59-63. PubMed ID: 11339054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The co-imaging of gamma camera measurements of aerosol deposition and respiratory anatomy.
    Conway J; Fleming J; Bennett M; Havelock T
    J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):123-30. PubMed ID: 23517170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhaled aerosol particle dosimetry in mice: a review.
    Méndez LB; Gookin G; Phalen RF
    Inhal Toxicol; 2010 Dec; 22 Suppl 2():15-20. PubMed ID: 21142796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of particle parameters in the evaluation of exposure-dose-response relationships of inhaled particles.
    Oberdorster G
    Inhal Toxicol; 1996; 8 Suppl():73-89. PubMed ID: 11542496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment methods of inhaled aerosols: technical aspects and applications.
    Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
    Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicology Studies for Inhaled and Nasal Delivery.
    Wolff RK
    Mol Pharm; 2015 Aug; 12(8):2688-96. PubMed ID: 25915006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the respiratory tract on inhaled materials.
    Dahl AR; Bond JA; Petridou-Fischer J; Sabourin PJ; Whaley SJ
    Toxicol Appl Pharmacol; 1988 May; 93(3):484-92. PubMed ID: 3285522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers.
    Cass LM; Brown J; Pickford M; Fayinka S; Newman SP; Johansson CJ; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():21-31. PubMed ID: 10429837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation.
    Ball D; Blanchard J; Jacobson-Kram D; McClellan RO; McGovern T; Norwood DL; Vogel W; Wolff R; Nagao L
    Toxicol Sci; 2007 Jun; 97(2):226-36. PubMed ID: 17369604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.